Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon beta-1a · 2 trials · 1 indication
ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.
ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.
| Arm | Type | Description |
|---|---|---|
| Interferon beta-1a 44 mcg SC | ACTIVE_COMPARATOR | Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks). |
| Ocrelizumab | EXPERIMENTAL | Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week. |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1a | DRUG | - |
| Ocrelizumab-matching placebo | DRUG | - |
| Ocrelizumab | DRUG | - |
| Interferon beta-1a-matching placebo | DRUG | - |
Inclusion Criteria: * Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010) * At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening) * Neu...
Interferon beta-1a is used for the treatment of Relapsing Multiple Sclerosis. It is an investigational drug in Phase 3 clinical development, studied as an active comparator in trials evaluating ocrelizumab. The completed trials enrolled a total of 1,656 participants across multiple countries.
Interferon beta-1a is developed by Roche Holding AG, traded under the ticker RHHBY. The company is conducting Phase 3 clinical trials for this drug in Relapsing Multiple Sclerosis. Roche is the sponsor of the studies listed under the NCT numbers NCT01247324 and NCT01412333.
Interferon beta-1a is in Phase 3 clinical development for Relapsing Multiple Sclerosis. It is not FDA approved and remains investigational. The drug has been studied in two completed Phase 3 trials, both of which were randomized, double-blind, and active-controlled.
Interferon beta-1a has been studied in two completed Phase 3 trials: NCT01247324 with 821 participants and NCT01412333 with 835 participants. Both trials compared ocrelizumab with Interferon beta-1a (Rebif) in participants with Relapsing Multiple Sclerosis. The trials were conducted in multiple countries including the United States, Argentina, and various European nations.
Interferon beta-1a is also known as Rebif, as indicated in the clinical trial titles. The trials compared ocrelizumab with Interferon beta-1a (Rebif) in participants with Relapsing Multiple Sclerosis. This alternative name helps identify the drug in clinical research contexts.